MedPath

AstraZeneca

AstraZeneca logo
🇬🇧United Kingdom
Ownership
Public
Employees
89.9K
Market Cap
$270.3B
Website
http://www.astrazeneca.co.uk
Introduction

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

Phase 3
Completed
Conditions
Zollinger-Ellison Syndrome
First Posted Date
2004-03-17
Last Posted Date
2010-11-19
Lead Sponsor
AstraZeneca
Target Recruit Count
25
Registration Number
NCT00079833
Locations
🇫🇷

Research Site, Saint Germain en Laye, France

ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2
Completed
Conditions
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
First Posted Date
2004-02-26
Last Posted Date
2013-08-02
Lead Sponsor
AstraZeneca
Registration Number
NCT00014690
Locations
🇺🇸

AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2004-02-11
Last Posted Date
2014-07-16
Lead Sponsor
AstraZeneca
Target Recruit Count
174
Registration Number
NCT00077025
Locations
🇻🇪

Research Site, Valencia, Venezuela

Iressa Versus Docetaxel (Taxotere)

Phase 3
Completed
Conditions
Non-Small-Cell Lung Carcinoma
First Posted Date
2004-01-23
Last Posted Date
2011-05-13
Lead Sponsor
AstraZeneca
Target Recruit Count
1440
Registration Number
NCT00076388
Locations
🇹🇷

Research Site, Izmir, Turkey

🇦🇷

Research site, El Palomar, Argentina

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease
COPD
First Posted Date
2004-01-15
Last Posted Date
2016-12-02
Lead Sponsor
AstraZeneca
Target Recruit Count
1100
Registration Number
NCT00076089
Locations
🇿🇦

ALTANA Pharma, Cities in South Africa, South Africa

The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

Phase 3
Completed
Conditions
Asthma
First Posted Date
2004-01-15
Last Posted Date
2016-12-02
Lead Sponsor
AstraZeneca
Target Recruit Count
822
Registration Number
NCT00076076
Locations
🇺🇦

ALTANA Pharma, Cities in the Ukraine, Ukraine

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Phase 2
Completed
Conditions
Intracerebral Hemorrhage
First Posted Date
2004-01-14
Last Posted Date
2013-01-04
Lead Sponsor
AstraZeneca
Target Recruit Count
600
Registration Number
NCT00075959
Locations
🇺🇸

Research Site, Marshfield, Wisconsin, United States

CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

Phase 1
Completed
Conditions
Prostatic Neoplasms
First Posted Date
2004-01-07
Last Posted Date
2012-06-06
Lead Sponsor
AstraZeneca
Target Recruit Count
8
Registration Number
NCT00075192
Locations
🇺🇸

Research Site, Smyrna, Tennessee, United States

Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

Phase 3
Completed
Conditions
Asthma
First Posted Date
2003-11-19
Last Posted Date
2016-10-25
Lead Sponsor
AstraZeneca
Target Recruit Count
819
Registration Number
NCT00073177
Locations
🇵🇪

ALTANA Pharma, Cities in Peru, Peru

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

Phase 2
Suspended
Conditions
Carcinoma, Renal Cell
Kidney Neoplasms
First Posted Date
2003-07-31
Last Posted Date
2011-01-26
Lead Sponsor
AstraZeneca
Registration Number
NCT00065572
Locations
🇺🇸

Research Site, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath